Count | |
4 | |
16 | |
1 | |
4 | |
2 | |
2 | |
1 | |
Physostigmine/*analogs & derivatives/*pharmacology/therapeutic use | 1 |
1 | |
1 | |
1 | |
1 | |
1 | |
1 | |
2 | |
1 | |
1 | |
1 | |
1 | |
Physostigmine/*analogs & derivatives/*chemical synthesis/chemistry | 2 |
Physostigmine/adverse effects/*analogs & derivatives/therapeutic use | 1 |
3 | |
4 | |
7 | |
7 | |
4 | |
3 | |
4 | |
4 | |
3 | |
6 | |
5 | |
1 | |
14 | |
1 | |
1 | |
17 | |
1 | |
1 | |
3 | |
2 | |
5 | |
10 | |
3 | |
2 | |
1 | |
1 | |
1 | |
1 | |
8 | |
2 | |
6 | |
1 | |
3 | |
1 | |
1 | |
7 | |
2 | |
2 | |
3 | |
1 | |
37 | |
1 | |
3 | |
39 | |
3 | |
1 | |
2 | |
22 | |
8 | |
1 | |
1 | |
16 | |
10 | |
4 | |
3 | |
3 | |
20 | |
31 | |
12 | |
18 | |
1 | |
2 | |
2 | |
2 | |
1 | |
1 | |
2 | |
2 | |
2 | |
1 | |
3 | |
10 | |
1 | |
4 | |
1 | |
3 | |
2 | |
2 | |
2 | |